[Expression of mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase type 2 in human atria during chronic atrial fibrillation: study of 25 cases]
- PMID: 17565863
[Expression of mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase type 2 in human atria during chronic atrial fibrillation: study of 25 cases]
Abstract
Objective: To investigate the mRNA and protein expression of mineralocorticoid receptor (MR) and 11-beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2), which plays a crucial role in the human heart to confer specificity on MR, in patients with chronic atrial fibrillation.
Methods: Twenty-five patients of rheumatic heart valve disease, 12 with sinus rhythm, and 13 with chronic atrial fibrillation for 6 months or over, underwent transthoracic echocardiography and mitral/aortic valve replacement operation during which right atrial lateral wall tissue samples were obtained and left atrial lateral wall tissue samples were obtained from 14 of them in addition. Realtime quantitative PCR was used to determine the mRNA expression of MR and 11betaHSD2 and Western blotting was employed to detect the protein expression of MR and 11betaHSD2 in the atrial myocardium.
Results: The left atrial diameters increased markedly in the atrial fibrillation group as compared to the sinus rhythm group (P < 0.01). The mRNA expression of MR in the right atrium of the patients with atrial fibrillation was 5.37 +/- 1.15, significantly higher than that of the patients with sinus rhythm (2.67 +/- 1.09, P < 0.01), the mRNA expression of MR in the left atrium of the patients with atrial fibrillation was 5.19 +/- 1.14, significantly higher than that of the patients with sinus rhythm (270 +/- 0.82, P < 0.01). The mRNA expression of 11betaHSD2 in the right atrium of the patients with atrial fibrillation was 0.86 +/- 0.14, significantly higher than that of the patients with sinus rhythm (0.33 +/- 0.12, P < 0.01), and the mRNA expression of 11betaHSD2 in the left atrium of the patients with atrial fibrillation was 0.95 +/- 0.15, significantly higher than that of the patients with sinus rhythm (0.37 +/- 0.10, P < 0.01). The protein expression of MR in the right atrial tissue of the patients with atrial fibrillation was 1.65 +/- 0.72, significantly higher than that of the patients with sinus rhythm (0.86 +/- 0.33, P < 0.01); and the protein expression of MR in the left atrial tissue of the patients with atrial fibrillation was 1.72 +/- 0.62, significantly higher than that of the patients with sinus rhythm (0.97 +/- 0.37a, P < 0.05). The protein expression of 11betaHSD2 in the right atrial tissue of the patients with atrial fibrillation was 1.18 +/- 0.64, significantly higher than that of the patients with sinus rhythm (0.71 +/- 0.21, P < 0.05); and the protein expression of 11betaHSD2 in the left atrial tissue of the patients with atrial fibrillation was 1.36 +/- 0.58, significantly higher than that of the patients with sinus rhythm (0.85 +/- 0.15, P < 0.05). The mRNA expression and protein expression of MR and 11betaHSD2 were not significantly different between the left atria and right atria both in the fibrillation and sinus groups (all P > 0.05).
Conclusion: The mRNA expression and protein expression of MR and 11betaHSD2 are upregulated in atrial fibrillation and aldosterone antagonists may be effective to arrest the development of sustained atrial fibrillation.
Similar articles
-
[Atrial 11beta-hydroxysteroid dehydrogenase type 2 expression in rheumatic heart disease patients with or without atrial fibrillation].Zhonghua Xin Xue Guan Bing Za Zhi. 2008 May;36(5):385-9. Zhonghua Xin Xue Guan Bing Za Zhi. 2008. PMID: 19100026 Chinese.
-
[Study on expression of mineralocorticoid receptor in human atria during atrial fibrillation].Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Feb;35(2):114-8. Zhonghua Xin Xue Guan Bing Za Zhi. 2007. PMID: 17445401 Chinese.
-
Angiotensin II receptor type 1 is upregulated in atrial tissue of patients with rheumatic valvular disease with atrial fibrillation.J Thorac Cardiovasc Surg. 2010 Aug;140(2):298-304. doi: 10.1016/j.jtcvs.2009.10.035. Epub 2010 Jan 18. J Thorac Cardiovasc Surg. 2010. PMID: 20080265
-
[Hemodynamic consequences of atrial fibrillation].Przegl Lek. 2003;60(1):30-4. Przegl Lek. 2003. PMID: 12884644 Review. Polish.
-
[Pathology of atrial fibrillation].J Cardiol. 1999 Mar;33 Suppl 1:47-52. J Cardiol. 1999. PMID: 10342136 Review. Japanese.
Cited by
-
Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.Int J Cardiol. 2013 Oct 15;168(6):5135-42. doi: 10.1016/j.ijcard.2013.08.022. Epub 2013 Aug 15. Int J Cardiol. 2013. PMID: 23993726 Free PMC article. Review.
-
Pharmacological management of atrial fibrillation: one, none, one hundred thousand.Cardiol Res Pract. 2011 Apr 26;2011:874802. doi: 10.4061/2011/874802. Cardiol Res Pract. 2011. PMID: 21577272 Free PMC article.
-
Insights into the Role of Galectin-3 as a Diagnostic and Prognostic Biomarker of Atrial Fibrillation.Dis Markers. 2023 Oct 9;2023:2097012. doi: 10.1155/2023/2097012. eCollection 2023. Dis Markers. 2023. PMID: 37849915 Free PMC article. Review.
-
Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation.Br J Pharmacol. 2010 Apr;159(8):1581-3. doi: 10.1111/j.1476-5381.2010.00675.x. Br J Pharmacol. 2010. PMID: 20388187 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical